Viemed Healthcare, Inc. (VMD) stock
VMDNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3020% below fair value
$9.17+0.06 (+0.66%)
Close on Nov 13, 2026Market cap $349.27MP/E 24.1Yield –
Viemed Healthcare r&d expenses
Research and development expenses are spending on new products and technology.
Viemed Healthcare's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.18M, down 32.3% year over year. For fiscal 2025 it was $3.02M, down 1.7% from the year before. The highest annual figure on record is $3.07M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.02M | -1.7% |
| FY2024 | Dec 31, 2024 | $3.07M | +10.3% |
| FY2023 | Dec 31, 2023 | $2.78M | +3.2% |
| FY2022 | Dec 31, 2022 | $2.70M | +27.8% |
| FY2021 | Dec 31, 2021 | $2.11M | +94.8% |
| FY2020 | Dec 31, 2020 | $1.08M | +27.7% |
| FY2019 | Dec 31, 2019 | $848.00K | – |
| FY2018 | Dec 31, 2018 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $501.00K | -35.4% |
| Q2 FY2026 | Jun 30, 2026 | $504.00K | -40.5% |
| Q1 FY2026 | Mar 31, 2026 | $579.00K | -27.4% |
| Q4 FY2025 | Dec 31, 2025 | $598.00K | -25.5% |
| Q3 FY2025 | Sep 30, 2025 | $775.00K | +2.4% |
| Q2 FY2025 | Jun 30, 2025 | $847.00K | +11.7% |
| Q1 FY2025 | Mar 31, 2025 | $797.00K | +6.3% |
| Q4 FY2024 | Dec 31, 2024 | $803.00K | +23.3% |
| Q3 FY2024 | Sep 30, 2024 | $757.00K | +27.7% |
| Q2 FY2024 | Jun 30, 2024 | $758.00K | 0.0% |
| Q1 FY2024 | Mar 31, 2024 | $750.00K | -3.8% |
| Q4 FY2023 | Dec 31, 2023 | $651.00K | -9.8% |
| Q3 FY2023 | Sep 30, 2023 | $593.00K | -11.5% |
| Q2 FY2023 | Jun 30, 2023 | $758.00K | +12.8% |
| Q1 FY2023 | Mar 31, 2023 | $780.00K | +23.4% |
| Q4 FY2022 | Dec 31, 2022 | $722.00K | +18.0% |
| Q3 FY2022 | Sep 30, 2022 | $670.00K | +16.3% |
| Q2 FY2022 | Jun 30, 2022 | $672.00K | +15.3% |
| Q1 FY2022 | Mar 31, 2022 | $632.00K | +86.4% |
| Q4 FY2021 | Dec 31, 2021 | $612.00K | +54.9% |
| Q3 FY2021 | Sep 30, 2021 | $576.00K | +137.0% |
| Q2 FY2021 | Jun 30, 2021 | $583.00K | +115.1% |
| Q1 FY2021 | Mar 31, 2021 | $339.00K | +94.8% |
| Q4 FY2020 | Dec 31, 2020 | $395.00K | +94.6% |
| Q3 FY2020 | Sep 30, 2020 | $243.00K | +16.8% |
| Q2 FY2020 | Jun 30, 2020 | $271.00K | +33.5% |
| Q1 FY2020 | Mar 31, 2020 | $174.00K | -25.6% |
| Q4 FY2019 | Dec 31, 2019 | $203.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $208.00K | – |
| Q2 FY2019 | Jun 30, 2019 | $203.00K | – |
| Q1 FY2019 | Mar 31, 2019 | $234.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | – |
| Q1 FY2018 | Mar 31, 2018 | $0 | – |
See a number that looks wrong?